PRKAA2 (Protein Kinase AMP-Activated Catalytic Subunit Alpha 2)

Finally, using functional studies, we developed a multivariate model that accurately predicted BCL-X L dependence in RCC. Our studies offer biomarkers for patient stratification and credential BCL-X L as a subtype agnostic vulnerability in difficult-to-treat RCCs.

This study elucidates cellular heterogeneity, the epigenetic regulatory landscape, and the key genes driving ccRCC progression. The integration of multi-omics data offers novel insights into precise diagnostic strategies and therapeutic interventions, highlighting the pivotal role of genes such as YBX3.

In summary, we constructed a prognostic signature based on insulin signaling pathway genes. The excellent performance and applicability of our model underscores its advantages and reliability as a clinical tool. Moreover, we validated SLC2A1 was an independent prognostic factor in a HCC independent cohort.

This study provides the first comprehensive analysis of LDAGs in EC, establishing robust prognostic and diagnostic gene signatures with strong biological relevance. These signatures support a metabolism-driven framework for EC classification and may offer potential clinical utility in early detection, risk stratification, and personalized treatment.

The proposed four-gene signature provides a novel tool for prognosis prediction and offers new insights for risk stratification and individualized therapy. Further multicenter validation and mechanistic studies are warranted.

Our findings provide strong evidence that the FRG-derived signature/nomogram can effectively predict both prognosis and therapeutic response in HNSCC.

All data demonstrated that USP18 acted as an oncogene in LUAD via interacting with POU4F1/PRKAA2 axis.

AMPK emerges as a crucial regulator in OM post radiotherapy and chemotherapy, implicating sister chromatid separation, where DCs may play a pivotal role. Aloisine and Teniposide appear promising for OM prevention or treatment associated with these treatments.

RT‒qPCR and immunohistochemical staining validated the expression levels of the model's molecular markers. Overall, our AERG-related model shows promise for predicting outcomes and guiding the selection of tailored and precise therapies for gastric cancer patients.

Vitamin D has been shown to inhibit the proliferation and migration of colon cancer cells and reduce the expression of oncogenes. Therefore, vitamin D holds substantial potential for the diagnosis and treatment of CRC.

The depletion of PRKAA2 enhanced the erastin-induced inhibition effect on cell growth, and notably increased the levels of MDA, ROS, iron, and Fe2+, while decreased GSH level in NSCLC cells...The results discovered that PRKAA2 accelerated the malignant progression, diminished apoptosis and ferroptosis in NSCLC through SLC7A11/GSH/GPX4 pathway. This study provide a novel target in the application of PRKAA2 for NSCLC treatment.

This nomogram was validated and showed good predictive performance, with area under the curve (AUC) values for 1-year, 3-year, and 5-year OS of 0.895, 0.765, and 0.728, respectively. Our findings underscore the profound impact of prognostic genes on the immune response and prognostic outcomes in BC, indicating that they can provide new avenues for personalized BC treatment and potentially improve clinical outcomes.